Global health continues to be a field where Global North actors see themselves as leaders. Although the decolonising global health movement has exposed the deep inequities inherent within the architecture of global health,
this movement, prone to elite capture, faces several institutional barriers that prevent meaningful shifts in power.
This executive summary highlights lessons learned from the longer-standing experiences of delivering LAIs for other chronic conditions in the fields of mental health and addiction offer insights into the use of newly available LAIs for HIV prevention and treatment. A socio-ecological framework was used to discuss issues surrounding the implementation of LAIs for all three types of conditions and explore ways to maximize potential benefits for HIV.
This report highlights the urgent need to consider innovative strategies to connect BLCW with PrEP services. As part of a NIMH EHE supplement project, the UCLA CHIPTS received funding to develop and pilot an implementation strategy to increase PrEP awareness and optimize PrEP uptake among BLCW through the use of the PlushCare telemedicine application.
This project was led by researchers from the University of California, Los Angeles and Charles R. Drew University of Medicine and Science in collaboration with the California Community Foundation to advise and provide insights on how to reach communities of color and those hardly reached to educate, build trust, and disseminate vaccines in South Los Angeles given historical experiences with medical mistrust. The efforts center around three goals, which are to: (1) Facilitate community, public, private, and governmental partnerships to reduce, COVID-19 vaccine inequity. (2) Educate communities of color in South LA about the COVID-19 vaccines through virtual town halls, and (3) Navigate communities of color in South LA on how to access available COVID-19 vaccines.
Summary of recommendations by Alma Guerrero, Department of Pediatrics, UCLA for the COVID-19 Roundtable Providers Summit on Tuesday, August 31, 2021. The recommendations focused on mobilizing service providers, improving patient-provider interaction, and the increase of vaccination rates.
The resource guide is organized as a list containing the information of various community partners that were invited speakers at the COVID-19 Community Leadership Summit. The information provided is related to COVID-19 vaccination efforts and incorporates a point of contact for any additional information if needed. The resource guide is meant to be shared to support on-going efforts to increase COVID-19 vaccines.
National Asian & Pacific Islander HIV/AIDS Awareness Day Reflection by Wei-Ti Chen that discusses the importance of providing culturally sensitive family-centered self-management interventions for Asian Pacific Americans living with HIV. The reflection also focuses on how acculturation had an impact on patient-healthcare and was contributing to HIV stigma and stress.
Report Summary by Laura M. Bogart that describes medical mistrust as a key contributor to racial/ethnic health and healthcare disparities in the U.S, the serious health consequences for people living with and at risk for HIV, and how medical mistrust also can affect views about HIV.
Taking Strategic Action to Address Substance Use in California – EHE Regional Meeting Summary Report
Addressing substance use in California was identified as a key priority for the Ending the HIV Epidemic (EHE) Regional Response across California’s EHE Phase 1 counties. On October 20 and October 27, 2020, CHIPTS and the CHPRC hosted a two-part EHE Regional Meeting. This event brought together over 100 stakeholders from California’s EHE Phase 1 counties, as well as other partners working at the intersection of HIV and substance use across the state, to discuss how to move evidence-based strategies forward to address substance use. The report is a summary of the event and key findings that will address substance use in CA EHE Phase 1 counties.
HIV Prevention Trials Network (HPTN) 083 is a randomized, active-controlled, double-blind clinical trial that began in December 2016. The study has compared the safety and efficacy of two drugs for use as PrEP among a population at increased risk of HIV infection.